Under construction – not a live service
Sign in
Taking people in ArgentinaNo phase

Studies biomarkers that may predict Alzheimer's in people with inherited mutations

Looks for signs that may predict Alzheimer's disease in adults carrying a gene mutation.

Plain-language title generated from the registry record
Registry title: Dominantly Inherited Alzheimer Network (DIAN)

Key facts

Where
Buenos Aires and Salta, ArgentinaSee the 2 sites

Where in Argentina

  • Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia" (FLENI) Instituto de Investigaciones Neurológicas Raúl CorreaBuenos Aires, ArgentinaTaking people
  • Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI)Salta, ArgentinaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Washington University School of Medicine
Trial code
NCT00869817
Record updated
5 October 2026
Original description
The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.Read full original descriptionShow less

Dominantly Inherited Alzheimer Network (DIAN)

The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.

Inclusion: Written informed consent obtained from participant and collateral source prior to any study-related procedures; Aged 18 (inclusive) or older and the child of an affected individual (clinically or by testing) in a pedigree with a known mutation for ADAD; Cognitively normal to very mild or mild cognitive impairment (CDR score range 0-1.0). Primary enrollment will focus on the recruitment of asymptomatic adult children who are more than 15 years younger than the estimated age of symptom onset. Enrollment of new participants with moderate cognitive impairment is allowed with the prior approval of the DIAN Coordinating Center; Has two persons who are not their full-blooded siblings who can serve as collateral sources for the study; Fluent in a language approved by the DIAN Coordinating Center at about the 6th grade level (international equivalent) or above.

Exclusion: Medical or psychiatric illness that would interfere in completing initial and follow-up visits; Under age 18; Requires nursing home level care; Has no one who can serve as a study informant.

ClinicalTrials.gov NCT00869817